AstraZeneca says rare disease drug shows improvements in inherited bone disorder despite missing key trial goal

AstraZeneca shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for hypophosphatasia (HPP), an inherited metabolic disease, saying the drug showed improvements despite missing its key trial goal.

Detected & updated continuously · Source: Nebula